-
Product Insights
NewLikelihood of Approval Analysis for Idiopathic Pulmonary Fibrosis
Overview How likely is it that the drugs in Idiopathic Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AM-1476 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AM-1476 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AM-1476 in Idiopathic Pulmonary Fibrosis Drug Details: AM-1476 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vardenafil Hydrochloride in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vardenafil Hydrochloride in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vardenafil Hydrochloride in Pulmonary Arterial Hypertension Drug Details: Vardenafil hydrochloride...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Taladegib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taladegib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Solid Tumor Drug Details: Taladegib (LY-2940680) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Taladegib in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Taladegib in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Taladegib in Idiopathic Pulmonary Fibrosis Drug Details: Taladegib (LY-2940680) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Myelodysplastic Syndrome Drug Details: Briquilimab (AMG-191) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Chronic Urticaria Or Hives Drug Details: Briquilimab (AMG-191)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Idiopathic Pulmonary Fibrosis Drug Details: Fipaxalparant (HZN-825) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fipaxalparant in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fipaxalparant in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fipaxalparant in Systemic Sclerosis (Scleroderma) Drug Details: Fipaxalparant (HZN-825) is under...